Interview with Padraig Somers, General Manager, Helsinn Birex
Mr. Somers, can you please introduce us to the Helsinn Group and its unique in-licensing model? Helsinn is a Swiss-based, private company owned by the Braglia family. The Braglias have…
Address: Novo Nordisk Ireland, 2nd Floor, 2 Hume St. Dublin 2,Ireland
Tel: 1850 665665
Web: http://www.novonordisk.ie/documents/home_page/document/index.asp
General information:
Irish office: 3/4 Upper Pembroke Street, Dublin 2
Global headquarters: Bagsværd, Denmark
Irish workforce: 24 employees
Global workforce: More than 31,300 employees
International production facilities in seven countries
Product areas
Diabetes care
Hormone replacement therapy (HRT)
Haemostasis management
Growth hormone therapy.
Clinical research:
Before any medicine is available for doctors to prescribe, it must be granted a license by the government. Therefore, all medicines have to be tested in appropriate patients to ensure that they reach the standards of safety and efficacy required by governmental agencies around the world. This is achieved by conducting clinical trials in which patients freely volunteer to try new medicines so that relevant data can be obtained. All clinical trials must conform to globally accepted scientific and ethical standards before they can proceed.
Novo Nordisk is committed to ensuring that all its products meet the highest quality standards and are rigorously tested by performing clinical trials in collaboration with doctors and nurses around the world, including sites in Ireland.
Novo Nordisk way:
In 1923, our Danish founders began a journey to change diabetes.
Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes.
Our ambition is to strengthen our leadership in diabetes. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aspire to change possibilities in haemophilia and other serious chronic conditions where we can make a difference. Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
We never compromise on quality and business ethics
Our business philosophy is one of balancing financial, social and environmental considerations – we call it ‘The Triple Bottom Line’
We are open and honest, ambitious and accountable, and treat everyone with respect
We offer opportunities for our people to realise their potential.
Every day, we must make difficult choices, always keeping in mind, what is best for patients, our employees and our shareholders in the long run.
It’s the Novo Nordisk Way.
Haemophilia and Eating Disorders.
Diabetes Care.
Hormone Replacement Therapy.
Mr. Somers, can you please introduce us to the Helsinn Group and its unique in-licensing model? Helsinn is a Swiss-based, private company owned by the Braglia family. The Braglias have…
Ms. Dickens, in our interview with your Sanofi colleague Jan Hendrix in Belgium last month, he commented that it is amazing how diversified this company has become in just the…
Can you give us a sense of the history of this company and its Irish roots? The company started life in the UK and has always been a GI franchise…
Mr. Hanlon, can you please begin by introducing Clonmel Healthcare to our readers? Clonmel Healthcare was founded by an Irish family in the 1970’s. During this time, its primary goal…
Mr. Hynds, you were personally instrumental in leading the establishment of Actavis in Ireland in 2008. You commented at the time, ‘Historically, Actavis grew by acquisition in other markets, but…
Mr. Martin, you were appointed as Genzyme’s GM for UK and Ireland last month after having spent a decade at the organization. Robin Kenselaar, Head of Genzyme EMEA, noted that…
Mr. Looney, what has it been like to run this business for 26 years? Looking back, what can you say that you have built? It has certainly been an exciting…
Dr. Coveney, what motivated you to start this company? I had been working for the multinationals for a number of years—Schering Plough, and a number of other organizations. In 1999,…
In 2008, MSD began building a human vaccine facility in Carlow—a 220MN EUR investment that the company expanded upon last year with an additional 7Mn EUR. What is the importance…
Mr. O’Leary, when an article in The Guardian last year profiled you and your work, it was titled “Resurrecting the Celtic Tiger.” More recently, Time Magazine put Taoiseach Enda Kenny…
To what extent do you believe Ireland has been successful in building the knowledge economy it set out to create during the 1980’s? I think we have been hugely successful—and…
This interview also features the comments of Geraldine Murphy, Managing Director of Leo Pharma, Ireland. Ms. Murphy, your transition to your current position was precipitated by a major refocusing that…
See our Cookie Privacy Policy Here
